Bursa Malaysia (KLSE) Stock Investment Portal

The Group is also investing heavily in Artificial Intelligence (AI) technologies to further automate the
diagnosis and management of diseases for patients. “AI doctors” are expected to be part of the
capabilities of i-Medic™ in the near future.

Stock

Stock: [UCREST]: UCREST BERHAD

2019-10-16 09:45 | Report Abuse

Digital health or telemedicine outlook on global scale is expected to increase to USD118B by the year
2025, and we expect the market in most developed as well as developing countries to grow in tandem
over the next few years. The Minister of Health in Malaysia has announced that the country will be on
trajectory of digital health in the next three years and we expected to have higher adoption rate.
The Group started the research and development work of the digital health platform approximately 5
years ago and the product is officially launched and well adopted over the past three years. i-Medic™
was developed to enable doctors to provide medical consultation and prescription to remote patients
based on the aggregated Electronic Medical Records and regularly uploaded vital signs taken from
mobile medical devices.
i-Medic™ is first launched in China targeting the high-end patients with the membership packages for
chronic disease management and the Group continues to expand on this market through doctors or
hospitals. Today, there are doctors and patients in China, Taiwan, Singapore, Indonesia, Malaysia,
Russia, Middle East and the USA using i-Medic™ for online medical consultations. These are largely
self-pay customers who have high awareness of their health.
In addition to the high-end patient market, the Group has also developed a model specifically for the
mass market through the public hospitals. The number of user licenses sold has increased dramatically
over the past two years. The Group will continue to expand its influence in the public hospitals or
ministry of health to establish the dominance in this market.
In the past fiscal year, the Group has stepped up and will continue to increase its investment in R&D on
developing new technologies and capabilities in its core product - i-Medic™ targeting the
pharmaceutical and medical insurance applications.

Stock

Stock: [UCREST]: UCREST BERHAD

2019-10-16 09:45 | Report Abuse

extraction from chairman's statement...The Group has expanded its products to pharmaceutical companies allowing online feedback of side
effects and efficacy. The digital pharma platform is currently being rolled out in Malaysia and it is
expected to expand into the Asia region. i-Medic™ will also track the medication prescribed and also
track the usage of the medication including timely reminders to ensure patient adherence. Educational
medical knowledge is disseminated to the patients directly to increase the medical knowledge and
brand awareness.
Insurance is the major payor of the medical expenses in most countries and insurers are rushing to
embark on digital insurance and digital health. The Group has invested resources to research and
develop breakthrough technologies in i-Medic™ that would disrupt the insurance business today and
the product will be launched in second half of the fiscal year. The Group signed a partnership deal with
Inova, a Third-Party Administrator that has presence in the USA and Asian countries to market the
i-Medic™ products in these countries. Since USA is leading in digital health and it is growing rapidly,
we expect this territory to be a major revenue contributor for our FYE 2020 onwards.

Stock

Stock: [UCREST]: UCREST BERHAD

2019-10-16 09:34 | Report Abuse

accumulate and hold.

Stock

Stock: [APPASIA]: APPASIA BERHAD

2019-10-15 11:29 | Report Abuse

go steady

Stock

Stock: [KNM-WB]:

2019-10-15 09:22 | Report Abuse

nice.